Name | 4-[(4-fluorophenyl)methyl]-2-(4-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione |
---|---|
Synonyms |
2-p-tolyl-4-(4-fluorobenzyl)-1,2,4-thiadiazolidine-3,5-dione
UNII-RA72G28VE9 4-((4-fluorophenyl)methyl)-2-(4-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione |
Description | CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site[1]. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test[2]. |
---|---|
Related Catalog | |
Target |
RGS4:30 nM (IC50) RGS8:11 μM (IC50) RGS16:3.5 μM (IC50) RGS19:0.12 μM (IC50) |
In Vivo | CCG50014 (10, 30, or 100 nM) attenuates the nociceptive responses during the late phase in a dose-dependent manner[2]. |
References |
Molecular Formula | C16H13FN2O2S |
---|---|
Molecular Weight | 316.35000 |
Exact Mass | 316.06800 |
PSA | 72.24000 |
LogP | 2.55650 |
Storage condition | -20℃ |
RIDADR | NONH for all modes of transport |
---|
~39% 883050-24-6 |
Literature: THE REGENTS OF THE UNIVERSITY OF MICHIGAN; Neubig, Richard; Blazer, Levi; Husbands, Stephen; Larsen, Scott; Traynor, John Patent: US2012/277273 A1, 2012 ; Location in patent: Page/Page column 22-23 ; |